Data Sheet (Cat.No.T85731)

TargetMol

ART0380

Chemical Properties



CAS No. : 2267316-76-5

Formula: C18H24N6O2S

Molecular Weight: 388.49

Storage: Store at low temperature,Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	ART0380 is a potent, selective, orally available, ATP-competitive ATR kinase inhibitor (IC50=51.7 nM) with antitumor activity for the study of ataxia telangiectasia mutated (ATM) cancer.
Targets(IC50)	ATM/ATR
In vivo	ART0380 is a potent and selective ATR inhibitor with a compelling in vitro and in vivo pharmacological profile and is currently in Phase 2 clinical studies in patients with advanced or metastatic solid tumors as monotherapy and in combination with DNA damaging agents (NCT04657068 and NCT05798611). ART0380 has a favorable human PK profile suitable for both intermittent and continuous once-daily (QD) dosing, characterized by dose-proportional increases in exposure and low variability. [2]

Solubility Information

Solubility	DMSO: 250 mg/mL (643.52 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5741 mL	12.8703 mL	25.7407 mL
5 mM	0.5148 mL	2.5741 mL	5.1481 mL
10 mM	0.2574 mL	1.287 mL	2.5741 mL
50 mM	0.0515 mL	0.2574 mL	0.5148 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Pilie PG, et al. Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types. Clin Cancer Res. 2024 Feb 28.

Carroll CL, et al. Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers. J Med Chem. 2024 Dec 26;67(24):21890-21904.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481